Examining how interleukin-6 affects glucagon's role in amino acid regulation
Interplay Between Interleukin-6 and Glucagon in the Regulation of Human Amino Acid and Protein Homeostasis
This study is testing how a substance called interleukin-6 affects the hormone glucagon's ability to manage amino acids in the body, using healthy volunteers.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 26 (estimated) |
| Ages | 18 Years to 50 Years |
| Sex | All |
| Sponsor | University Hospital, Basel, Switzerland Academic / other |
| Drugs / interventions | tocilizumab |
| Locations | 1 site (Basel) |
| Trial ID | NCT06721910 on ClinicalTrials.gov |
What this trial studies
This proof-of-concept study investigates the interaction between interleukin-6 (IL-6) and glucagon in healthy volunteers. Participants will receive either a saline infusion or an IL-6 receptor blocker, followed by hormone and amino acid infusions to simulate fasting and fed states. Blood samples will be collected to assess how IL-6 influences glucagon's ability to lower blood amino acid concentrations. The study aims to clarify the role of IL-6 in protein and amino acid homeostasis.
Who should consider this trial
Good fit: Ideal candidates are healthy adults aged 18 to 50 with a stable body weight and a BMI between 18.5 and 25 kg/m2.
Not a fit: Patients with chronic conditions, unstable body weight, or those currently taking medications may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could enhance our understanding of amino acid regulation, potentially leading to improved treatments for conditions related to glucagon resistance.
How similar studies have performed: While the specific interplay of IL-6 and glucagon is less explored, similar studies on cytokines and metabolic regulation have shown promising results.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion criteria: * Age 18 to 50 years * BMI 18.5 - 25 kg/m2 * Stable body weight in the past 6 months before study initiation * Women should be anovulatory on non-cyclic hormone replacement or hormonal contraception Exclusion criteria: * Previous medical history for any chronic condition in the last three months, active disease or abnormal physical examination as verified by a qualified physician * Body weight unstable in the past 6 months * Use of tobacco/nicotine * Alcohol consumption \>30g/day * Participation in an investigational drug trial within the past two months * Current intake of any drugs (prescribed, over the counter or recreational) * Known allergy to tocilizumab * Pregnant or lactating women, * Inability or unwillingness to provide informed consent
Where this trial is running
Basel
- University Hospital Basel — Basel, Switzerland (Recruiting)
Study contacts
- Principal investigator: Beckey Trinh, MD, PhD — University Hospital, Basel, Switzerland
- Study coordinator: Beckey Trinh, MD, PhD
- Email: beckey.trinh@usb.ch
- Phone: +41 328 58 53
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.